碘[<sup>131</sup>I]化钠口服溶液治疗分化型甲状腺癌场所空气中<sup>131</sup>I浓度检测

doi:10.13491/j.issn.1004-714X.2022.02.012

中国辐射卫生

2022, Vol. 31

Issue (2): 197-203 DOI: 10.13491/j.issn.1004-714X.2022.02.012

论著

本期目录 | 过刊浏览 | 高级检索

碘[¹³¹I]化钠口服溶液治疗分化型甲状腺癌场所空气中¹³¹I浓度检测

刘明^1,2, 耿建华², 郑容², 梁颖^1,2, 李高峰³

1. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院深圳医院核医学科，广东深圳 518116;
2. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院核医学科，北京 100021;
3. 北京格物时代科技发展有限公司，北京 102600

Radioactive concentration of ¹³¹I in the air of treatment workplaces for differentiated thyroid cancer with sodium iodide [¹³¹I] oral solution

LIU Ming^1,2, GENG Jianhua², ZHENG Rong², LIANG Ying^1,2, LI Gaofeng³

1. National Cancer center/National Clinical Research Center for Cancer/ Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116 China;
2. National Cancer center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021 China;
3. Beijing Explore Times Technology Co. Ltd, Beijing 102600 China

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (548 KB) HTML ( )
输出: BibTeX | EndNote (RIS)

摘要目的研究核医学科碘[¹³¹I]化钠口服溶液治疗分化型甲状腺癌（DTC）患者时，治疗场所空气中¹³¹I放射性浓度，评估工作人员内照射剂量。方法选取某医院核医学科DTC患者¹³¹I住院治疗的工作场所。分别对¹³¹I服药区和¹³¹I治疗病房空气进行气体采样，通过低本底伽玛谱仪探测样本，经计算空气中¹³¹I的活度浓度，估算工作人员受到的内照射剂量。结果在¹³¹I服药区，服药3 h内活度浓度为3～187 Bq/m³。患者服药期间及患者服药后3 h、在服药处停留5～30 min，内照射剂量分别为0.08～0.50 μSv及0.00～0.04 μSv。患者服药当天病房空气中¹³¹I的活度浓度最高，可达3 091 Bq/m³；患者出院后，病房活度浓度逐渐降低，在48 h内浓度为10～242 Bq/m³。出院后48 h内在病房停留5～30 min，内照射剂量为0.01～14.11 μSv 。结论 ¹³¹I治疗DTC患者服药期间空气中¹³¹I活度浓度较高，建议采用远程给药或观察窗给药。患者住院期间，病房内¹³¹I活度浓度最高，建议除医护人员外，禁止其他人员进入病房。患者出院后，尽量延后进入病房的时间，以减少内照射剂量。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	刘明
	耿建华
	郑容
	梁颖
	李高峰

关键词 ：核医学科, ¹³¹I治疗, 住院, 气溶胶, 活度浓度, 内照射

收稿日期: 2021-10-21

X591

通讯作者: 耿建华，E-mail：gengjean@163.com E-mail: gengjean@163.com

作者简介: 刘明（1995—），男，山东聊城人，初级职称，从事核医学技术工作。E-mail：495718439@qq.com

引用本文:

刘明, 耿建华, 郑容, 梁颖, 李高峰. 碘[¹³¹I]化钠口服溶液治疗分化型甲状腺癌场所空气中¹³¹I浓度检测[J]. 中国辐射卫生, 2022, 31(2): 197-203.
LIU Ming, GENG Jianhua, ZHENG Rong, LIANG Ying, LI Gaofeng. Radioactive concentration of ¹³¹I in the air of treatment workplaces for differentiated thyroid cancer with sodium iodide [¹³¹I] oral solution. , 2022, 31(2): 197-203.

链接本文:

http://www.zgfsws.com/CN/10.13491/j.issn.1004-714X.2022.02.012 或 http://www.zgfsws.com/CN/Y2022/V31/I2/197

[1] 赫捷, 陈万清. 2016年中国肿瘤登记年报[M]. 北京: 清华大学出版社, 2017: 72.
He J, Chen WQ. Chinese cancer registray annual report[M]. Beijing: Tsinghua University Press, 2017: 72
[2] 赫捷, 陈万清. 2015年中国肿瘤登记年报[M]. 北京: 清华大学出版社, 2017: 66.
He J, Chen WQ. Chinese cancer registray annual report[M]. Beijing: Tsinghua University Press, 2017: 66
[3] 吴茜, 王荣福. 放射性核素¹³¹I在甲亢治疗中的应用现状和进展[J]. 标记免疫分析与临床,2015,22(1):66-68. DOI: 10.11748/bjmy.issn.1006-1703.2015.01.021
Wu Q, Wang RF. Overview and Progress of ¹³¹I in the Treatment of Hyperthyroidism[J]. Lab Immun Clini Medi, 2015, 22(1): 66-68. DOI: 10.11748/bjmy.issn.1006-1703.2015.01.021
[4] Lauri C, Di Traglia S, GalliF, et al. Current status of PET imaging of differentiated thyroid cancer with second generation radiopharmaceuticals[J]. QJ Nucl Med Mol Imaging, 2015, 59(1): 105-115
[5] 中华医学会内分泌学分会, 中华医学会外科学分会内分泌学组, 中国抗癌协会头颈肿瘤专业委员会, 等. 甲状腺结节和分化型甲状腺癌诊治指南[J]. 中华核医学与分子影像杂志, 2013, 33(2): 96-115. DOI:10.3760/cma.j.issn.2095-2848.2013.02.003.
Chinese Society of Endocrinology, Chinese Society of Nuclear Medicine, Head and neck tumor Committee of China Anti Cancer Association, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid[J]. Chin J Nucl Med Mol Imag, 2013, 33(2): 96-115. DOI: 10.3760/cma.j.issn.2095-2848.2013.02.003.
[6] Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer[J]. Clin Endocrinol(Oxf), 2014, 81(Suppl 1): 1-122. DOI: 10.1111/cen.12515
[7] Pacini F, Castagna MG, Brilli L, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2012, 23(Suppl 7): 110-119. DOI: 10.1093/annonc/mds230
[8] 中华医学会核医学分会. 分化型甲状腺癌术后¹³¹I治疗临床路径专家共识(2017版)[J]. 中华核医学与分子影像杂志,2018,38(6):416-419. DOI: 10.3760/cma.j.issn.2095-2848.2018.06.009
Chinese Society of Nuclear Medicine. 2017 expert consensus for clinical pathways on postoperative ¹³¹I treatment of differentiated thyroid carcinoma[J]. Chin J Nucl Med Mol Imag, 2018, 38(6): 416-419. DOI: 10.3760/cma.j.issn.2095-2848.2018.06.009
[9] 高再荣. 《分化型甲状腺癌术后¹³¹I治疗临床路径专家共识(2017版)》解读[J]. 中华核医学与分子影像杂志,2018,38(6):420-421. DOI: 10.3760/cma.j.issn.2095-2848.2018.06.010
Gao ZR. Interpretation for 2017 expert consensus for clinical pathways on postoperative ¹³¹I treatment of differentiated thyroid carcinoma[J]. Chin J Nucl Med Mol Imag, 2018, 38(6): 420-421. DOI: 10.3760/cma.j.issn.2095-2848.2018.06.010
[10] Kluczewska-Galka A, Janowski P, Mroz T, et al. I-131 Internal Contamination and committed dose assessment among nuclear medicine medical personnel[J]. Radiat Prot Dosimetry, 2018, 179(3): 275-281. DOI: 10.1093/rpd/ncx274
[11] Tran XH, Huynh TP, Nguyen VH. Estimating the internal dose for 131I production workers from air sampling method[J]. Radiat Prot Dosimetry, 2017, 175(1): 58-64. DOI: 10.1093/rpd/ncw269
[12] 刘明, 耿建华, 梁颖. 核医学治疗分化型甲状腺癌场所空气中¹³¹I浓度的研究进展[J]. 中国辐射卫生,2019,28(6):734-736. DOI: 10.13491/j.issn.1004-714X.2019.06.036
Liu M, Geng JH, Liang Y. Research progress of ¹³¹I concentration in the air in the 131I thyroid carcinoma treatment site[J]. Chin J Radiol Health, 2019, 28(6): 734-736. DOI: 10.13491/j.issn.1004-714X.2019.06.036
[13] 中华人民共和国国家质量监督检验检疫总局、中国国家标准化管理委员会. GB/T 16148—2009放射性核素摄入量及内照射剂量估算规范[S]. 北京: 中国标准出版社, 2009.
General Administration of quality supervision, inspection and Quarantine of the people's Republic of China and China National Standardization Administration Committee. GB/T 16148—2009 Specification for assessments of intakes and internal doses of radionuclides[S]. Beijing: Standard press of China, 2009
[14] 中华人民共和国国家卫生健康委员会. GBZ 120—2020 核医学放射防护要求 [S]. 北京: 中国标准出版社, 2020.
National Health Commission. GBZ 120—2020 Requirements for radiological protection in nuclear medicine[S]. Beijing: Standard press of China, 2020.
[15] 严源, 金潇, 邵明刚. I-131治疗场所放射性废气排放源项调查与评价[J]. 同位素,2019,32(6):388-39. DOI: 10.7538/tws.2018.youxian.068
Yan Y, Jin X, Shao MG. Investigation and evaluation of the radioactive waste gas source terms discharged from the nuclide I-131 treatment site[J]. J Isot, 2019, 32(6): 388-39. DOI: 10.7538/tws.2018.youxian.068
[16] Jiemwutthisak P, Sritongkul N, Chaudakshetrin P, et al. Air Monitoring to control the intake of airborne radioiodine-131 contaminants by nuclear medicine workers[C]//6th Annual Scientific Meeting on Challenges of Quality Assurance in Radiation Medicine. Phitsanulok, 2012: 87-90.
[17] Ferdous J, Sharmin N, Begum A. Airborne Radioactivity in hot lab of nuclear medicine[J]. J Sci Res, 2017, 9(2): 159-166. DOI: 10.3329/jsr.v9i2.29873
[18] 朱卫国, 侯长松, 佟鹏, 等. 我国五省核医学工作场所放射性核素浓度分析[J]. 中国辐射卫生,2020,29(3):249-252. DOI: 10.13491/j.issn.1004-714X.2020.03.012
Zhu WG, Hou CS, Tong P, et al. Analysis of radionuclide concentration in workplaces of nuclear medicine in five provinces of China[J]. Chin J Radiol Health, 2020, 29(3): 249-252. DOI: 10.13491/j.issn.1004-714X.2020.03.012